Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$44.85 USD
+0.15 (0.34%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $44.85 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Price, Consensus and EPS Surprise
BMY 44.85 +0.15(0.34%)
Will BMY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMY
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for BMY
The Melanoma Research Foundation to host the DC Miles for Melanoma 5K
Dividend Champion, Contender, And Challenger Highlights: Week Of April 28
2 Very Cheap Turnarounds Yielding Up To 7%
Wall Street Breakfast: What Moved Markets
Amgen’s Blincyto data send Cullinan higher